Synergism between COX-3 inhibitors in two animal models of pain

dc.creatorMuñoz, J.
dc.creatorNavarro, C.
dc.creatorNoriega, V.
dc.creatorPinardi,
dc.creatorSierralta, F.
dc.creatorPrieto, J. C.
dc.creatorMiranda, H. F.
dc.date.accessioned2019-03-11T12:59:21Z
dc.date.available2019-03-11T12:59:21Z
dc.date.created2019-03-11T12:59:21Z
dc.date.issued2010
dc.identifierInflammopharmacology, Volumen 18, Issue 2, 2018, Pages 65-71
dc.identifier09254692
dc.identifier10.1007/s10787-009-0019-7
dc.identifierhttps://repositorio.uchile.cl/handle/2250/164987
dc.description.abstractObjective and design: The antinociception induced by the intraperitoneal coadministration in mice of combinations of metamizol and paracetamol was evaluated in the tail flick test and orofacial formalin test. Methods: The antinociception of each drugs alone and the interaction of the combinations was evaluated by isobolographic analysis in the tail-flick and in the formalin orofacial assay of mice. Results: Mice pretreated with the drugs demonstrated that the antinociception of metamizol and paracetamol is dose-dependent. The potency range on the antinocifensive responses for metamizol or paracetamol was as follows: orofacial (Phase II) > orofacial (Phase I) > tail flick. In addition, the coadministration of metamizol with paracetamol induced a strong synergistic antinociception in the algesiometer assays. Both drugs showed effectiveness in inflammatory pain. Conclusion: These actions can be related to the differential selectivity of the drugs for inhibition of COX isoforms and also to
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceInflammopharmacology
dc.subjectAnalgesia
dc.subjectMetamizol
dc.subjectPain
dc.subjectParacetamol
dc.subjectSynergism
dc.titleSynergism between COX-3 inhibitors in two animal models of pain
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución